1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,031 | 0,036 | 18:21 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15:02 | Genflow Biosciences PLC Announces Final Results | 67 | ACCESS Newswire | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
| 14:12 | Genflow Biosciences - Final Results | 4 | RNS | ||
| Di | Genflow Biosciences PLC Announces Expansion of Confidentiality Agreements | 122 | ACCESS Newswire | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
| Di | Genflow Biosciences - Expansion of Confidentiality Agreements | 1 | RNS | ||
| GENFLOW BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 20.04. | Genflow kooperiert mit Acuitas bei Technologie zur Verabreichung von Gentherapien | 1 | Investing.com Deutsch | ||
| 20.04. | Genflow partners with Acuitas for gene therapy delivery tech | 2 | Investing.com | ||
| 20.04. | Genflow Biosciences PLC Announces Strategic Technology Collaboration | 237 | ACCESS Newswire | Genflow Biosciences Enters Strategic Technology Collaboration with Acuitas Therapeutics - Fully Funded, Non-Dilutive Access to World-Class LNP Delivery Platform LONDON, UK / ACCESS Newswire / April... ► Artikel lesen | |
| 20.04. | Genflow Biosciences - Strategic Technology Collaboration | - | RNS | ||
| 13.04. | Genflow expands patent coverage to muscular disease treatments | 4 | Investing.com | ||
| 13.04. | Genflow Biosciences PLC Announces International Patent Publication | 262 | ACCESS Newswire | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
| 13.04. | Genflow Biosciences - International Patent Publication | 2 | RNS | ||
| 08.04. | Genflow reports sustained safety in aged dog gene therapy trial | 3 | Investing.com | ||
| 08.04. | Genflow Biosciences - Update on the Dog Study | - | RNS | ||
| 31.03. | Genflow Biosciences PLC Announces Total Voting Rights | 208 | ACCESS Newswire | LONDON, UK / ACCESS Newswire / March 31, 2026 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company") announces that the total issued share capital of the Company as at 31 March... ► Artikel lesen | |
| 31.03. | Genflow Biosciences - Total Voting Rights | 2 | RNS | ||
| 05.03. | Genflow Biosciences PLC Announces Issue of Equity & PDMR Notifications | 255 | ACCESS Newswire | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
| 05.03. | Genflow Biosciences - Issue of Equity & PDMR Notifications | 3 | RNS | ||
| 02.03. | Genflow Biosciences PLC Announces Result of GM | 243 | ACCESS Newswire | Results of General Meeting LONDON, UK / ACCESS Newswire / March 2, 2026 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company") a leading European-based biotechnology company... ► Artikel lesen | |
| 02.03. | Genflow Biosciences - Result of GM | 1 | RNS | ||
| 02.03. | Genflow Biosciences PLC Announces Receipt of First Tranche of Grant | 289 | ACCESS Newswire | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen |
1 2 3 4 Weiter >>
67 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDIGENE | 0,021 | -12,60 % | Medigene: Zurückziehung - 18.11.2025 | ||
| CRISPR THERAPEUTICS | 44,330 | +2,04 % | What's the Next Big Thing After GLP-1 Drugs? CRISPR Therapeutics May Have the Answer. | ||
| CO.DON | 0,015 | 0,00 % | EQS-AFR: CO.DON AG i.l.: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: CO.DON AG i.l.
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
CO.DON AG i.l.: Vorabbekanntmachung über die... ► Artikel lesen | |
| SIRONA BIOCHEM | 0,037 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 24.04.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 24.04.2026.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 24.04.2026.ISIN NameCA46658Y1034 J2... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,242 | -1,08 % | Pacific Biosciences of California (PACB) Dips More Than Broader Market: What You Should Know | ||
| TME PHARMA | 0,070 | +0,14 % | TME Pharma NV: TME Pharma Announces Publication of NOX-A12 "Triple Therapy" Phase 1/2 Expansion Arm A Findings from GLORIA trial in Nature Communications | TME Pharma Announces Publication of NOX-A12 "Triple Therapy" Phase 1/2 Expansion Arm A Findings from GLORIA trial in Nature Communications Berlin, Germany, April 16, 2026, 08.00am CET - TME Pharma... ► Artikel lesen | |
| DENALI THERAPEUTICS | 16,010 | +0,38 % | What Makes Denali Therapeutics (DNLI) One of the Best Biotech Stocks to Invest in | ||
| REPLENISH NUTRIENTS | 0,077 | -7,23 % | Replenish Nutrients Expands Revolving Credit Facilities by $1.95 Million to Support Beiseker Scale-Up and Licensing Growth | ||
| GLOW LIFETECH | 0,027 | 0,00 % | Glow Lifetech Corp.: Glow Lifetech Expands Distribution with Two of Canada's Largest Cannabis Retailers, Launches New Product Innovation and Advances National Growth Strategy | Toronto, Ontario--(Newsfile Corp. - April 30, 2026) - Glow Lifetech Corp. (CSE: GLOW) (OTCID: GLWLF) (FSE: 9DO) ("Glow" or the "Company") is pleased to provide a commercial update highlighting continued... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 3,330 | +6,66 % | Voyager Therapeutics, Inc.: Voyager IV-Delivered CNS Gene Therapies Featured in Multiple Presentations at ASGCT 2026, Including Late Breaker on Tau-Targeted VY1706 for Alzheimer's Disease | ||
| NEOVACS | 0,000 | 0,00 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 08.04.2026 | Das Instrument B4A1 CH0208062627 MEIER TOBLER GRP AG NAM. EQUITY wird cum Kapitalmassnahme gehandelt am 08.04.2026 und ex Kapitalmassnahme am 09.04.2026 The instrument B4A1 CH0208062627 MEIER TOBLER... ► Artikel lesen | |
| ADAPTIMMUNE THERAPEUTICS | 0,013 | -13,51 % | Adaptimmune Therapeutics PLC: Adaptimmune Announces Changes to Board and Executive Leadership Team | Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 17, 2025) - Adaptimmune Therapeutics plc (OTC Pink: ADAPY) ("Adaptimmune" or the "Company") today announced changes... ► Artikel lesen | |
| BIOAGE LABS | 14,400 | -0,35 % | BioAge Labs, Inc.: BioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRP | 120 mg and newly announced 60 mg once-daily doses each achieved =85% median hsCRP reductions in participants with obesity and elevated baseline inflammation BGE-102 was well tolerated across all dose... ► Artikel lesen | |
| BIOVAXYS TECHNOLOGY | 0,025 | -10,71 % | Biovaxys Technology Corp (2): Biovaxys Technology has no material changes | ||
| TELO GENOMICS | 0,032 | +6,67 % | Telo Genomics Corp.: Telo Genomics Announces Study with University of Athens to Advance Next-Generation MRD Risk Stratification in Multiple Myeloma | Vancouver, British Columbia--(Newsfile Corp. - April 14, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and... ► Artikel lesen |
GENFLOW BIOSCIENCES PLC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,024 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GENFLOW BIOSCIENCES PLC finden Sie auf Wallstreet Online.